Wells Fargo Begins Coverage of Bio-Techne (TECH) Stock, Gives PT of $59

On May 30, Wells Fargo began coverage on Bio-Techne Corporation (NASDAQ:TECH)’s stock with an “Overweight” rating and a price objective of $59.00, as reported by The Fly. The firm’s analyst, Brandon Couillard, lauded the company’s strong financial position. Bio-Techne Corporation (NASDAQ:TECH)’s net interest expense in Q3 2025 came in at $0.8 million, reflecting a fall of $2.3 million as compared to the prior year because of reduced net debt levels.

Wells Fargo Begins Coverage on Bio-Techne (NASDAQ:TECH) Stock, Gives PT of $59

A team of scientists wearing lab coats and protective eyewear in a research laboratory, intently looking into microscopes and analyzing results.

Its bank debt on the balance sheet as of the end of Q3 was $330 million. The company’s balance sheet had $140.7 million in cash, while its total leverage ratio was well below one time EBITDA.

As per Wells Fargo, Bio-Techne Corporation (NASDAQ:TECH)’s unique portfolio remains well-placed to deliver sustained above-average organic revenue and earnings growth. Furthermore, Bio-Techne Corporation (NASDAQ:TECH) is exposed to high-growth verticals, including good manufacturing practice reagents, spatial biology, and precision diagnostics, among others. Overall, the firm opines that the recent pullback in the shares provides a strong entry point.

During Q3 2025, the company’s pharma end market continued to improve, mainly from its large pharma partners, which resulted in a strong performance in the cell therapy and protein analysis instrumentation businesses. Bio-Techne Corporation (NASDAQ:TECH)’s continued emphasis on profitability led to a 34.9% adjusted operating margin, implying a 190 bps increase as compared to the prior-year period.

Bio-Techne Corporation (NASDAQ:TECH) is engaged in developing, manufacturing, and selling life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None.